

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5706155

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>			<b>Execution Date</b>
PHILIP WILSON HOWARD			01/13/2016
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	MEDIMMUNE LIMITED		
<b>Street Address:</b>	MILSTEIN BUILDING		
<b>Internal Address:</b>	GRANTA PARK		
<b>City:</b>	CAMBRIDGE		
<b>State/Country:</b>	UNITED KINGDOM		
<b>Postal Code:</b>	CB21 6GH		
<b>PROPERTY NUMBERS Total: 1</b>			
<b>Property Type</b>	<b>Number</b>		
<b>Application Number:</b>	15911592		
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	(608)662-1276		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	6086621277		
<b>Email:</b>	maschur@casimirjones.com		
<b>Correspondent Name:</b>	MELISSA E. KOLOM		
<b>Address Line 1:</b>	2275 DEMING WAY		
<b>Address Line 2:</b>	SUITE #310		
<b>Address Line 4:</b>	MIDDLETON, WISCONSIN 53562		
<b>ATTORNEY DOCKET NUMBER:</b>	MEWB-35694.307		
<b>NAME OF SUBMITTER:</b>	MELISSA E. KOLOM		
<b>SIGNATURE:</b>	/Melissa E. Kolom/		
<b>DATE SIGNED:</b>	09/06/2019		
<b>Total Attachments: 11</b>			
source=2019-09-06_35694-307-Executed-Assignment-Howard-Medimmune#page1.tif			
source=2019-09-06_35694-307-Executed-Assignment-Howard-Medimmune#page2.tif			
source=2019-09-06_35694-307-Executed-Assignment-Howard-Medimmune#page3.tif			
source=2019-09-06_35694-307-Executed-Assignment-Howard-Medimmune#page4.tif			

source=2019-09-06\_35694-307-Executed-Assignment-Howard-Medimmune#page5.tif  
source=2019-09-06\_35694-307-Executed-Assignment-Howard-Medimmune#page6.tif  
source=2019-09-06\_35694-307-Executed-Assignment-Howard-Medimmune#page7.tif  
source=2019-09-06\_35694-307-Executed-Assignment-Howard-Medimmune#page8.tif  
source=2019-09-06\_35694-307-Executed-Assignment-Howard-Medimmune#page9.tif  
source=2019-09-06\_35694-307-Executed-Assignment-Howard-Medimmune#page10.tif  
source=2019-09-06\_35694-307-Executed-Assignment-Howard-Medimmune#page11.tif

Assignment of invention and PCT/EP2013/071341; PCT/EP2013/071342;  
PCT/EP2013/071343; PCT/EP2013/0171346; PCT/EP2013/017349; PCT/EP2013/071350;  
PCT/EP2013/071352  
Mewburn Ref: RJW/LP6936280; RJW/LP6936298; RJW/LP6936306; RJW/LP6936314;  
RJW/LP6936330; RJW/LP6936348; RJW/LP6936355 & Client Ref: Patent 1 WO; Patent 2  
WO; Patent 3 WO; Patent 4 WO; Patent 6 WO; Patent 7 WO; Patent 9 WO

## **ASSIGNMENT OF INVENTION & RELATED INTELLECTUAL PROPERTY RIGHTS**

### **PARTIES**

- (1) **HOWARD, PHILIP WILSON** c/o Medimmune Spriogen Business Unit, The QMB Innovation Centre, 42 New Road, London, E1 2AX, United Kingdom (the **Inventor**); and
- (2) **MEDIMMUNE LIMITED** incorporated and registered in England & Wales with company number 02451177 whose registered office is at Milstein Building, Granta Park, Cambridge, CB21 6GH, United Kingdom (the **Employer**).

### **BACKGROUND**

- (A) The Inventor is an inventor of the Invention for which the Patent Applications have been or will be filed. The contributions of the Inventor to the Invention were made in the course of the duties of the Inventor as an employee of the Employer, and either the circumstances were such that an invention might reasonably have been expected to result from the carrying out of those duties, or the nature of those duties was such that the Inventor had a special obligation to further the interests of the Employer's undertaking.
- (B) The Inventor and the Employer believe that, either by operation of law or by virtue of an agreement entered into by the Inventor and the Employer before the making of the Invention, the Employer was, at the time the Invention was made, entitled to the whole of the property in the contributions of the Inventor to the Invention.
- (C) In case the Employer for any reason was not, at the time the Invention was made, entitled to the whole of the property in the contributions of the Inventor to the Invention, and in order to provide documentary evidence that the Employer is the owner of both the legal title and the beneficial interest in the Patent Applications and in any contributions of the Inventor to the Invention, including any further contributions that the Inventor may make to the development or improvement of the Invention, the Inventor has agreed to execute this Assignment to assign to the Employer all his rights, title and interest in, to and arising from the Invention and the Patent Applications on the terms set out in this Assignment.

## **AGREED TERMS**

### **1. INTERPRETATION**

- 1.1 The definitions and rules of interpretation in this clause apply in this Assignment.

**Completion Applications** means the completion patent applications, short particulars of which are set out in Part 2 of the Schedule.

**Future Applications** means any future applications linked by one or more priorities to the Completion Applications and all matter contained in such future applications.

**Invention** means the invention or inventions entitled PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES, PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES, PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES, and PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES.

**Patent Applications** means the Priority Applications, the Completion Applications and the Future Applications and any and all:

- (a) national and regional phase applications of all such applications; and
- (b) divisions, continuations and continuations-in-part of all such applications; and
- (c) patents that may be granted pursuant to any of the aforesaid applications for their full period, including any re-issues, re-examinations, renewals, extensions and Supplementary Protection Certificates.

**Priority Applications** means the priority patent applications, short particulars of which are set out in Part 1 of the Schedule.

- 1.2 A **person** includes a natural person, corporate or unincorporated body (whether or not having separate legal personality) and that person's legal and personal representatives, successors and permitted assigns.

### **2. ASSIGNMENT**

In consideration of the sum of £1 (sufficiency and receipt of which the Inventor expressly acknowledges), the Inventor hereby assigns absolutely to the Employer all their right, title and interest in Canada, the United States and all other countries of the world in, to and arising from the Invention and, with

Assignment of invention and PCT/EP2013/071341; PCT/EP2013/071342;  
PCT/EP2013/071343; PCT/EP2013/0171346; PCT/EP2013/017349; PCT/EP2013/071350;  
PCT/EP2013/071352

Mewburn Ref: RJW/LP6936280; RJW/LP6936298; RJW/LP6936306; RJW/LP6936314;  
RJW/LP6936330; RJW/LP6936348; RJW/LP6936355 & Client Ref: Patent 1 WO; Patent 2  
WO; Patent 3 WO; Patent 4 WO; Patent 6 WO; Patent 7 WO; Patent 9 WO

effect from immediately prior to the filing of each, the Patent Applications  
including (but not limited to):

- (a) in respect of the Invention and any invention that shall be disclosed  
in, and all matter that shall be contained in, any of the Patent  
Applications, the right to file applications, claim priority from such  
applications, and prosecute and obtain grant of patent or other  
intellectual property protection in respect of any country, region or  
territory in the world;
- (b) in respect of each and any Patent Application:
  - (i) the right to claim priority from and to prosecute and obtain  
grant of patents; and
  - (ii) the right to file divisional applications based on the Patent  
Applications and to prosecute and obtain grant of patent on  
each and any such divisional application;
- (c) the right to extend to, or register in or in respect of any country,  
region or territory in the world, each and any of the Patent  
Applications and to extend to or register in, or in respect of, any  
country, region or territory in the world any patent or other intellectual  
property protection granted on any of such applications;
- (d) the absolute entitlement to any patents granted pursuant to any  
Patent Application; and
- (e) the right to bring, make, oppose or defend claims or actions, appeal  
proceedings and obtain relief (and to retain any damages recovered)  
in respect of any infringement, or any other cause of action arising  
from ownership of the Inventions and the Patent Applications,  
whether occurring before on or after the date of this Assignment.

### **3. FURTHER ASSURANCE**

The Inventor shall, at the Employer's cost, perform all further acts and things,  
and execute all further documents, required by law or which the Employer  
requests to vest in the Employer the full benefit of the right, title and interest  
assigned to the Employer under this Assignment, including (but not limited  
to):

- (a) documents required to be signed by or on behalf of the Inventor in  
the course of any and all Canadian or United States or any other  
applications which relate to the Invention or to any inventions that  
shall be disclosed in any of the Patent Applications;

Assignment of invention and PCT/EP2013/071341; PCT/EP2013/071342;  
PCT/EP2013/071343; PCT/EP2013/0171346; PCT/EP2013/017349; PCT/EP2013/071350;  
PCT/EP2013/071352

Mewburn Ref: RJW/LP6936280; RJW/LP6936298; RJW/LP6936306; RJW/LP6936314;  
RJW/LP6936330; RJW/LP6936348; RJW/LP6936355 & Client Ref: Patent 1 WO; Patent 2  
WO; Patent 3 WO; Patent 4 WO; Patent 6 WO; Patent 7 WO; Patent 9 WO

- (b) registration of the Employer as applicant for, or proprietor of, the Patent Applications; and
- (c) assisting the Employer in obtaining, defending and enforcing any of the Patent Applications, and assisting with any other proceedings which may be brought by or against the Employer by any third party or in the resolution of any question concerning the Invention, or the Patent Applications or any inventions that shall be disclosed in any of the Patent Applications.

#### **4. POWER OF ATTORNEY**

The Inventor and the Employer grant the firm of Mewburn Ellis LLP the power to insert in Part 3 of the Schedule to this Assignment any further identification of any existing or future patent applications in Canada or the United States or any other countries, regions or territories of the world, which shall fall within the scope of clause 2 above, or as may be necessary or desirable in order to comply with the rules of the United States Patent Office or the Canadian Patent Office or any other patent office for the recordal of this Assignment. It is agreed that Mewburn Ellis LLP has represented only the Employer and will continue to represent only the Employer with respect to this Assignment.

#### **5. ISSUE OF PATENTS**

The Inventor requests the US Commissioner of Patents and the relevant authorities in all countries, regions and territories of the world to issue any patents granted for the Invention or pursuant to any of the Patent Applications in the name of the Employer (either alone or jointly with any co-applicant) in accordance with this Assignment.

#### **6. WAIVER**

No failure or delay by a party to exercise any right or remedy provided under this Assignment or by law shall constitute a waiver of that or any other right or remedy, nor shall it preclude or restrict the further exercise of that or any other right or remedy. No single or partial exercise of such right or remedy shall preclude or restrict the further exercise of that or any other right or remedy.

Assignment of invention and PCT/EP2013/071341; PCT/EP2013/071342;  
PCT/EP2013/071343; PCT/EP2013/0171346; PCT/EP2013/017349; PCT/EP2013/071350;  
PCT/EP2013/071352  
Mewburn Ref: RJW/LP6936280; RJW/LP6936298; RJW/LP6936306; RJW/LP6936314;  
RJW/LP6936330; RJW/LP6936348; RJW/LP6936355 & Client Ref: Patent 1 WO; Patent 2  
WO; Patent 3 WO; Patent 4 WO; Patent 6 WO; Patent 7 WO; Patent 9 WO

**7. COUNTERPARTS**

This Assignment may be executed in any number of counterparts, each of which when executed shall constitute an original of this Assignment, but all the counterparts shall together constitute the same agreement.

**8. GOVERNING LAW AND JURISDICTION**

This Assignment shall be governed by and construed in accordance with the law of England and Wales. The parties agree that the courts of England and Wales shall have exclusive jurisdiction to settle any dispute or claim that arises out of or in connection with this Assignment.

Assignment of invention and PCT/EP2013/071341; PCT/EP2013/071342;  
PCT/EP2013/071343; PCT/EP2013/0171346; PCT/EP2013/017349; PCT/EP2013/071350;  
PCT/EP2013/071352  
Mewburn Ref: RJW/LP6936280; RJW/LP6936298; RJW/LP6936306; RJW/LP6936314;  
RJW/LP6936330; RJW/LP6936348; RJW/LP6936355 & Client Ref: Patent 1 WO; Patent 2  
WO; Patent 3 WO; Patent 4 WO; Patent 6 WO; Patent 7 WO; Patent 9 WO

### Schedule: The Patent Applications

#### Part 1: Priority Applications

Country	Application No.	Application Date	Title
US	61/712924	12 October 2012	PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF
US	61/712928	12 October 2012	PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF
US	61/784460	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/784477	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/784525	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/784291	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/784308	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/784328	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/784233	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/784249	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/784270	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/784362	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/784383	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/784421	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/798037	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/798072	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/798106	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/784162	14 March 2013	PYRROLOBENZODIAZEPINE-

Assignment of invention and PCT/EP2013/071341; PCT/EP2013/071342;  
PCT/EP2013/071343; PCT/EP2013/071346; PCT/EP2013/071349; PCT/EP2013/071350;  
PCT/EP2013/071352

Mewburn Ref: RJW/LP6936280; RJW/LP6936298; RJW/LP6936306; RJW/LP6936314;  
RJW/LP6936330; RJW/LP6936348; RJW/LP6936355 & Client Ref: Patent 1 WO; Patent 2  
WO; Patent 3 WO; Patent 4 WO; Patent 6 WO; Patent 7 WO; Patent 9 WO

			ANTIBODY CONJUGATES
US	61/784191	14 March 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
US	61/784207	14 March 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
US	61/794922	14 March 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
US	61/794954	14 March 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
US	61/794997	14 March 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES

## Part 2: Completion Applications

Application No.	Application Date	Title
PCT/EP2013/071341	11 October 2013	PYRROLOBENZODIAZEPINE - ANTI- PSMA ANTIBODY CONJUGATES
EP 13795435.0	11 October 2013	PYRROLOBENZODIAZEPINE - ANTI- PSMA ANTIBODY CONJUGATES
US 14/434812	11 October 2013	PYRROLOBENZODIAZEPINE - ANTI- PSMA ANTIBODY CONJUGATES
AU 2013328619	11 October 2013	PYRROLOBENZODIAZEPINE - ANTI- PSMA ANTIBODY CONJUGATES
BR BR1120150081738	11 October 2013	PYRROLOBENZODIAZEPINE - ANTI- PSMA ANTIBODY CONJUGATES
CA 2887894	11 October 2013	PYRROLOBENZODIAZEPINE - ANTI- PSMA ANTIBODY CONJUGATES
IN 1069/MUMNP/2015	11 October 2013	PYRROLOBENZODIAZEPINE - ANTI- PSMA ANTIBODY CONJUGATES
MX MX/A/2015/004416	11 October 2013	PYRROLOBENZODIAZEPINE - ANTI- PSMA ANTIBODY CONJUGATES
NZ 707486	11 October 2013	PYRROLOBENZODIAZEPINE - ANTI- PSMA ANTIBODY CONJUGATES
ZA 2015/02437	11 October 2013	PYRROLOBENZODIAZEPINE - ANTI- PSMA ANTIBODY CONJUGATES
KR 10-2015-7012364	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI- PSMA ANTIBODY CONJUGATES
PCT/EP2013/071342	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI- PSMA ANTIBODY CONJUGATES
EP 13785372.7	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI- PSMA ANTIBODY CONJUGATES

Assignment of invention and PCT/EP2013/071341; PCT/EP2013/071342;  
PCT/EP2013/071343; PCT/EP2013/0171346; PCT/EP2013/017349; PCT/EP2013/071350;  
PCT/EP2013/071352  
Mewburn Ref: RJW/LP6936280; RJW/LP6936298; RJW/LP6936306; RJW/LP6936314;  
RJW/LP6936330; RJW/LP6936348; RJW/LP6936355 & Client Ref: Patent 1 WO; Patent 2  
WO; Patent 3 WO; Patent 4 WO; Patent 6 WO; Patent 7 WO; Patent 9 WO

US 14/434818	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES
PCT/EP2013/071343	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES
EP 13788691.7	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES
US 14/434810	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES
AU 2013328621	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES
BR BR1120150081770	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES
CA 2887896	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES
IN 1072/MUMNP/2015	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES
MX MX/A/2015/004423	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES
NZ 707546	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES
ZA 2015/02267	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES
KR 10-2015-7012365	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES
PCT/EP2013/071346	11 October 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
EP 13785831.2	11 October 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US 14/434816	11 October 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
AU 2013328623	11 October 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
BR BR1120150081746	11 October 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
CA 2887895	11 October 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
IN 1090/MUMNP/2015	11 October 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
MX MX/A/2015/004449	11 October 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
NZ 707534	11 October 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES

Assignment of invention and PCT/EP2013/071341; PCT/EP2013/071342;  
PCT/EP2013/071343; PCT/EP2013/071346; PCT/EP2013/071349; PCT/EP2013/071350;  
PCT/EP2013/071352  
Mewburn Ref: RJW/LP6936280; RJW/LP6936298; RJW/LP6936306; RJW/LP6936314;  
RJW/LP6936330; RJW/LP6936348; RJW/LP6936355 & Client Ref: Patent 1 WO; Patent 2  
WO; Patent 3 WO; Patent 4 WO; Patent 6 WO; Patent 7 WO; Patent 9 WO

ZA 2015/02428	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
KR 10-2015-7012366	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
PCT/EP2013/071349	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
EP 13785373.5	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
US 14/434823	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
AU 2013328625	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
BR BR1120150082327	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
CA 2887897	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
IN 1094/MUMNP/2015	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
MX MX/A/2015/004421	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
NZ 707543	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
ZA 2015/02523	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
KR 10-2015-7012367	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
PCT/EP2013/071350	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
EP 13785374.3	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
US 14/434821	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
PCT/EP2013/071352	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI- CD22 ANTIBODY CONJUGATES
EP 13786186.0	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI- CD22 ANTIBODY CONJUGATES
US 14/434826	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI- CD22 ANTIBODY CONJUGATES
AU 2013328628	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI- CD22 ANTIBODY CONJUGATES
BR BR11201500823686	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI- CD22 ANTIBODY CONJUGATES

Assignment of invention and PCT/EP2013/071341; PCT/EP2013/071342;  
PCT/EP2013/071343; PCT/EP2013/071346; PCT/EP2013/071349; PCT/EP2013/071350;  
PCT/EP2013/071352  
Mewburn Ref: RJW/LP6936280; RJW/LP6936298; RJW/LP6936306; RJW/LP6936314;  
RJW/LP6936330; RJW/LP6936348; RJW/LP6936355 & Client Ref: Patent 1 WO; Patent 2  
WO; Patent 3 WO; Patent 4 WO; Patent 6 WO; Patent 7 WO; Patent 9 WO

CA 2887899	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES
IN 1115/MUMNP/2015	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES
MX MX/A/2015/004420	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES
NZ 707490	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES
ZA 2015/02524	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES
KR 10-2015-7012368	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES

**Part 3: Identification of some, but not necessarily all, patent applications falling within the scope of clause 2 of this Assignment**


Country/region	Application No.	Application Date	Title	Signature for Mewburn Ellis LLP

Assignment of invention and PCT/EP2013/071341; PCT/EP2013/071342;  
PCT/EP2013/071343; PCT/EP2013/0171346; PCT/EP2013/017349; PCT/EP2013/071350;  
PCT/EP2013/071352

Mewburn Ref: RJW/LP6936280; RJW/LP6936298; RJW/LP6936306; RJW/LP6936314;  
RJW/LP6936330; RJW/LP6936348; RJW/LP6936355 & Client Ref: Patent 1 WO; Patent 2  
WO; Patent 3 WO; Patent 4 WO; Patent 6 WO; Patent 7 WO; Patent 9 WO

Executed by **PHILIP HOWARD**

**WILSON** in the presence of:



SIGNATURE OF WITNESS

NAME: R.J. WATSON

ADDRESS: CITY TOWER, 40 BASINGHALL ST, LONDON, EC2V 5DE, UK

OCCUPATION: PATENT ATTORNEY

DATE: 13/1/16



SIGNATURE OF INVENTOR

Executed by **MEDIMMUNE**

**LIMITED** acting by

Christopher S Winter, an

Authorised Signatory, in the

presence of:



SIGNATURE OF WITNESS

NAME: R.J. WATSON

ADDRESS: CITY TOWER, 40 BASINGHALL ST, LONDON, EC2V 5DE, UK

OCCUPATION: PATENT ATTORNEY

DATE: 13/1/16



SIGNATURE